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ABSTRACT
BORIS, like other members of the ‘cancer/testis
antigen’ family, is normally expressed in testicular
germ cells and repressed in somatic cells, but is
aberrantly activated in cancers. To understand
regulatory mechanisms governing human BORIS
expression, we characterized its 5’-flanking region.
Using 5’ RACE, we identified three promoters,
designated A, B and C, corresponding to transcrip-
tion start sites at 1447, 899 and 658bp
upstream of the first ATG. Alternative promoter
usage generated at least five alternatively spliced
BORIS mRNAs with different half-lives determined
by varying 5’-UTRs. In normal testis, BORIS is
transcribed from all three promoters, but 84% of
the 30 cancer cell lines tested used only promoter(s)
A and/or C while the others utilized primarily
promoters B and C. The differences in promoter
usage between normal and cancer cells suggested
that they were subject to differential regulation.
We found that DNA methylation and functional
p53 contributes to the negative regulation of each
promoter. Moreover, reduction of CTCF in
normally BORIS-negative human fibroblasts
resulted in derepression of BORIS promoters.
These results provide a mechanistic basis for
understanding cancer-related associations between
haploinsufficiency of CTCF and BORIS derepres-
sion, and between the lack of functional p53 and
aberrant activation of BORIS.
INTRODUCTION
BORIS (Brother of the Regulator of Imprinted Sites), also
designated CTCFL (CTCF-like), is the mammalian
paralog of a highly conserved (1,2), multi-functional
chromatin factor encoded by a candidate tumor suppres-
sor gene, CTCF (3–6). Loukinov et al. (4,7) showed that in
humans and mice, these two genes encode polypeptides of
similar size that share a centrally positioned nearly
identical DNA-binding domain (DBD). The DBD is
composed of 11 Zn-ﬁngers (11ZF), including ten of the
classic DNA-binding C2H2-class and one (ZF 11) of the
C2HC-class capable of binding both single-strand DNA
and RNA (8). It is noteworthy that the 11 ZF DBD
regions in BORIS and CTCF are encoded by genomic
sequences, which display an accurate duplication of a
region containing all ZF-coding exons of the CTCF gene
from an early mammal. The accuracy of this duplication
in the human genome was maintained to the extent that
genomic nucleotide similarities between CTCF and
BORIS at individual intron–exon junctions approach
100% identity at the single nucleotide level (7).
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By virtue of this shared DNA-recognition domain,
BORIS can bind speciﬁcally to the same DNA target
sequences that interact with CTCF. However, the con-
sequences of BORIS or CTCF bound to the same site
would be expected to be diﬀerent. This is because the
amino- and carboxy-termini of BORIS and CTCF are
totally unrelated such that cofactors associated with
one would not partner with the other. Thus, there would
be diﬀerent functional outcomes depending on which one
of the two paralogs occupies a CTCF/BORIS-11ZF-
binding site (9,10).
Once bound to DNA, CTCF may function as a versatile
component of transcriptional chromatin insulators,
hormone-dependent silencers and promoter repressors or
activators (3–6). CTCF-binding sites have been mapped in
diﬀerentially methylated domains of imprinting control
regions (ICR) that regulate a parent-of-origin-dependent
mono-allelic expression within clusters of imprinted genes:
IGF2/H19 (11–13), Rasgrf-1 (14) DLK1/GTL2 (15),
AWT1/WT1-AS (16) and KvDMR (17) loci. In addition,
several functionally distinct, important, methylation-
sensitive CTCF/BORIS-binding sites involved in random
and/or imprinted X-chromosome inactivation (XCI)
choice have been mapped at the X-inactivation center
(Xic) (18–22).
Finally, a novel class of methylation-insensitive, but
CpG-containing CTCF/BORIS-target sites was found
and characterized in promoter regions of genes encoding
the X-linked cancer-testis antigens (CTA) MAGE-A1,
NY-ESO-1 (9,23) and SPAN-X (24). Promoters of CTA
genes are methylated and repressed in normal somatic
cells that express CTCF and not BORIS, but are
speciﬁcally demethylated and activated in testicular
germ cells and in cancer cells that express BORIS (9,23).
Vatolin et al. (9) and Hong et al. (23) have documented
co-expression of BORIS with other CTA genes in the
majority of cancer cell lines and primary breast, prostate,
colorectal and lung tumors tested. They also showed that
conditionally expressed BORIS can outcompete CTCF
in vitro and in vivo for binding to normally methylated
11ZF-target sites present in the silenced MAGE-A1 and
NY-ESO-1 promoters. In addition, within three days of
BORIS expression in normal cells, they observed both
demethylation and activation of these two genes. It was
also demonstrated that while CTCF is bound to the
repressed/methylated MAGE-A1 and NY-ESO-1 promo-
ters in normal human ﬁbroblasts, activation of the same
promoters in cancer cell lines is associated with in vivo
occupancy by BORIS of methylation-insensitive 11ZF-
target sites. Moreover, 12 other CTA genes that are
normally co-expressed in testis with BORIS but not in
somatic cells with CTCF were activated by ectopic
expression of BORIS in normal primary human ﬁbro-
blasts. In contrast, promoters of genes regulated by
methylation but not normally co-expressed with BORIS
in male germ cells failed to respond to ectopic expression
of BORIS (9). Similar ﬁndings on the important roles of
CTCF/BORIS-binding sites in regulation of the germ cell
speciﬁc ALF and SPAN-X genes, have been reported by
DeJong (25) and Larionov (24) laboratories, respectively.
Importantly, during male germ cell development,
CTA-expressing cells are also engaged in the process of
re-establishing paternal gene imprinting marks. This
suggests that binding of BORIS in place of CTCF to
shared targets, may be responsible for two eﬀects. The ﬁrst
is activation of CTA gene promoters in testis. The second
is re-setting of paternal ICR marks by remethylation in
mature diﬀerentiating testicular germ cells after erasure of
all gene imprinting marks in primordial germ cells (7,10).
Indeed, data from a recent publication have provided
strong support for the concept of BORIS-mediated
epigenetic regulation of paternal ICR re-methylation (10).
Taken together, these results strongly support the hypo-
theses that CTCF and BORIS act successively to govern
epigenetic states in normal male germ cell development,
while rivalry in binding to the same spectrum of DNA
sites caused by aberrant activation of BORIS in somatic
cells may be associated with cancer (4,7).
While the mechanisms governing regulation of CTCF
by its promoter have been explored by Klenova et al. (26),
data on BORIS promoter regulation has not been
described. This prompted us to investigate patterns of
BORIS expression in normal testicular germ cells, in
cancer cell lines, and in primary tumor tissues. We charac-
terized the 50-ﬂanking noncoding region of the gene with
expected regulatory (promoter) function. We mapped
three alternative promoters producing ﬁve alternatively
spliced 50-UTR and analyzed promoter usage in diﬀerent
cell types and tissues. We also showed that activity of
these promoters is negatively regulated by DNA methyla-
tion and by CTCF and p53.
MATERIALS AND METHODS
Cell lines and tissue samples
A total of 293 human embryonic kidney cells; normal
human dermal ﬁbroblasts (NHDF) (Cambrex, Rockland,
MD, USA), normal foreskin ﬁbroblasts BJ and 31 tumor
cell lines (Table 1) were used in this study. The majority of
tumor cell lines were maintained in RPMI 1640 supple-
mented with 10% heat inactivated FBS, 1% PSN
Antibiotic Mixture (Invitrogen, Carlsbad, CA, USA)
and 0.5% fungizone (Invitrogen). The 293, HeLa and
Co115 cell lines were grown in DMEM with 10% heat
inactivated FBS, 1% PSN and 0.5% fungizone. Normal
cells were grown in the media recommended by the ATCC
and NHDF in the media recommended by Cambrex.
K562 cells stably transfected with the temperature-
sensitive p53Val135 mutant, which adopts a wild-type
conformation at 328C, were previously described (27).
The p53/ H1299 parental cell line and the H1299 p53wt
cell line (28) were a generous gift from Dr Peter M.
Chumakov (Department of Molecular Genetics Lerner
Research Institute, Cleveland, Ohio, USA).
Demethylation studies were performed with NHDF
treated with 1 mM 5-aza-20-deoxycytidine (5-aza-dC)
(Sigma-Aldrich, St. Louis, MO, USA). Cells were
harvested at diﬀerent times after treatment and medium
containing 5-aza-dC was replaced with the fresh medium
every 48 h.
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Normal and tumor tissues were obtained from the
Tissue Bank of the Institute of Pathology of Lausanne.
Twenty-four human normal tissue samples from bone
marrow, bladder, heart, kidney, skin, colon, testis and
ovary and 26 tumor tissue samples from bladder, breast,
colon, kidney, lung, testis, ovary and endometrium were
analyzed. All tissue samples were examined histologically
by a pathologist (R.B.). The use of human tissue samples
during this study was in accordance to the guidelines of
the ethical committee of the Medical Faculty of Lausanne
(Switzerland).
Analysis of mRNA stability of BORIS alternative 5’UTRs
The mRNA half-life of BORIS was determined in K562
and Ovcar-8 cell lines treated with Actinomycin D (ActD).
Brieﬂy, Ovcar-8 cells were grown in 6-well tissue culture
plates for 24 h to achieve 80% conﬂuency. Next, cells
were treated for 10min, 30min, 1, 2, 4, 6, 8, 12, and 24 h
with 15 mg/ml of ActD dissolved in DMSO. Total RNA
was extracted before and after ActD treatment, and
mRNA levels were quantitated by real-time RT-PCR
(qPCR). For each sample, the amount of BORIS mRNA
was quantiﬁed relative to 1 mg of total RNA. First strand
cDNA was synthesized using 1 mg of total RNA (DNase-
treated) and alternative 50 UTRs of BORIS mRNA were
ampliﬁed using primers speciﬁc for each isoform (Table 2).
Serial 10-fold dilutions (from 300 000 to 30 molecules) of
cloned DNA for each alternative 50 UTRs were used as
a reference for the standard curve calculation. All qPCRs
were performed using the SYBR Green ﬂuorogenic dye
and data were analyzed using ABI system software.
RNA degradation curves were obtained by setting as
100% the maximum level of mRNA expression at Time 0
before treatment with ActD. mRNA levels determined at
times following Time 0 are expressed as a percentage of
the maximum value. The half-lives of alternatively spliced
50 UTR mRNAs was obtained from the logarithmically
transformed best-ﬁt line by linear regression analysis (29).
RT-PCR and northern blot analyses
RNAs were extracted from cultured cells using the
TRIzol LS Reagent (Invitrogen, Basel, Switzerland).
One-step RT-PCR was performed with 200 ng of total
RNA in 20 ml. BORIS expression was screened with the
Table 1. Cell lines used for screening of BORIS expression from the three diﬀerent promoters
Group Cell line Cancer type BORIS expression PrA% PrB% PrC% Methylation MS-SSCPa P53b
PrB PrC
A SNB-19 CNSc ++ 95 0 5 M M Mut
786-0 Kidney ++ 84 0 16 M M Mut
A498 Kidney + 65 0 35 M M Mut
ACHN Kidney + 78 0 22 M M Mut
CCRF-CEM Leukemia + 66 0 34 U/M U/M Mut
RPMI-8226 Leukemia + 61 0 39 U/M U/M Mut
HOP-92 Lung + 93 0 7 M M Mut
SK–MEL-2 Melanoma ++ 68 0 32 M M WT
OVCAR-3 Ovary ++ 83 0 17 M M WT
NCCIT Testis + 96 1 3 M M Mut
A/C HS578T Breast ++ 41 0 59 M M WT
MCF7 Breast ++ 43 0 57 M M Mut
MDA-MB-435 Breast + 50 1 49 M M Mut
HCT-116 Colon ++ 47 0 53 M M Mut
SW-620 Colon + 51 0 49 M M Mut
SN12C Kidney ++ 53 0 47 M M Mut
NCI-H522 Lung + 48 0 52 M M Mut
SK-OV-3 Ovary ++ 49 0 51 M M WT
C MDA-MB-231 Breast + 21 0 79 M M Mut
SNB-75 CNS ++ 36 0 64 M M WT
HCT-15 Colon ++ 33 0 67 M M Mut
HT29 Colon +++ 37 0 63 M M WT
HL-60 Leukemia + 39 0 61 M M Mut
MOLT-4 Leukemia ++ 25 0 74 M M Mut
SR Leukemia +++ 31 0 69 M M Mut
NCI-H322 Lung +++ 13 0 87 M M Mut
B COLO-205 Colon ++ 3 73 24 U/M U/M ?
K-562 Leukemia ++++ 3 80 18 U U Mut
MM-S1 Leukemia +++ 2 85 13 U U Mut
NCI/ARD-RES Ovary +++ 1 52 47 U U Del
OVCAR-8 Ovary +++ 0 96 4 U U ?
Normal cells BJ Fibroblast  – – – M M n/a
NHDF Fibroblast  – – – M M n/a
aU=unmethylated; M=methylated; U/M=partially methylated.
bMut=mutation; WT=wild type; Del=deletion (35).
cCNS=Central nervous system.
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primers RT-A3 50-AAGCCGCGAACGGAGACGAAG-30
and RT-B3 50-ACGCCTTCATCCACTTCCTCTTT-30.
Northern blot analyses were performed as described
previously (30).
Reverse transcription and qPCR
RNA was extracted from cultured cells as described below
from tumor cell lines (Table 1). Total RNA (3–4 mg) was
converted to cDNA using ThermoScript reverse tran-
scriptase kit (Invitrogen, Carlsbad, CA, USA) according
to manufacturer’s instructions.
qPCR analyses were preformed using the TaqMan
Universal PCR Master Mix or the PowerSYBR Green
PCR Master Mix (Applied Biosystems, Foster city, CA,
USA) and the Applied Biosystems 7900HT qPCR system.
For the analyses of BORIS transcripts expressed from
promoter A, primers were designed in the ﬁrst noncoding
exon nearest to promoter A+1 start site. For the analyses
of expression from promoter B, primers were engineered
to span the ﬁrst noncoding and coding exons. For the
analyses of expression from promoter C, primers were
selected by using the unique sequence of the ﬁrst coding
exon utilized only for promoter C. Primers and probes
were selected using Primer Express program, and optimal
experimental conditions were established for each set.
Sequences of the primers and probes are summarized in
Table 2. Primer/probe mixtures for human glyceralde-
hyde-3-phosphate dehydrogenase (HS99999905_m1) and
p53 (HS00153349_m1) were purchased as Predeveloped
Assay (Applied Biosystems, Foster City, CA, USA). Data
were analyzed by comparative Ct method and normalized
to the untreated control.
The RNA copy number generated from each promoter
was determined using a standard curve following the ABI
protocols. To determine transcript copy number, standard
curves were generated for each primer pair using 10-fold
serial dilutions of linearized plasmids containing known
copy numbers of the target PCR products. The threshold
cycle of each dilution was determined and plotted against
the log value of the cDNA copy number. Transcript
numbers for each experimental sample were interpolated
by its detection threshold value using the appropriate
standard curve. Expression levels were normalized to that
of the housekeeping gene, GAPDH. Standard curve
coordinates and ranges are shown in Table 3.
Table 2. Primers and probes used in real-time PCR
Name Primers sequences Probe
CTCF FW 50-TGACACAGTCATAGCCCGAAAA-30 6FAMTGATTTGGGTGTCCACTTGCGAAAGC-MGB
REV 50-TGCCTTGCTCAATATAGGAATGC-30
BORIS-MC FW 50-CCCATTGTGCCACCATCA-30 6FAMACGGAAAAGCGACCTAC-MGB
REV 50-AGCATGCAAGTTGCGCATAT-30
BORIS promA FW 50-CTTACTTCCCCCCCGGGT-30 6FAMCTCCTCCCTTCCTCA-MGB
REV 50-GCCTTGGGGTTGAAGTGGA-30
BORIS promB or FW 50-GCAGAGCCACAAGCCAAAG-30 6FAMAGTGGGCCGAGCAT-MGB
BORIS REV 50-ATCTCAGTGGCTGCCATAATGACT-30
BORIS promC or FW 50-CCCTTCTCCCCCCTATGGA-30 6FAMACCGCTTGCTTATTT-MGB
BORIS C1 REV 50-CCATAATGACTTGGCCTGTTTG-30
BORIS A1 FW 50-TCCCTTCCTCATCCACTTCAA-30 SYBR Green method
REV 50-GCTCAGAAAGGACAGAGATCTCAGT-30
BORIS A2 FW 50-CATCCACTTCAACCCCAAGC-30 SYBR Green method
REV 50-CTTTGGCTTGTGGGCTCTG-30
BORIS A3 FW 50-GCTCTCCTCCTCTCCTTATCCAC-30 SYBR Green method
REV 50-CCATACAGGGCACTGGGAGAC-30
hMYC-G FW 50-GTGCGGGAGCCAGTGAACT-30 SYBR Green method
REV 50-AAGATCCCAGCTCCTCAGCC-‘3
hMYC-N FW 50-GGCTCTGTGAGGAGGCAAGGTG-30 SYBR Green method
REV 50-GCTCTCTATTTGGAGTGGCGGG-30
CTCF ChIP PrA FW 50-CTCCTTATCCATTACCCACCACC-30 SYBR Green method
REV 50CAGTATCTCAGTGCCTCCTGTGG-30
CTCF ChIP PrB fw 50-CCCTGCCCCCACAGTACAT-30 SYBR Green method
rev 50-TTTTCCGCTCCGCGC-30
CTCF ChIP PrC fw 50-GGCCAGTCCCGGTCAAG-30 SYBR Green method
rev 50-AGCATGGGCTGTTCTGGG-30
Table 3. Real-time PCR standard curve coordinates and ranges
Plasmid Curve range
(copy number)
Standard curves
Slope R2
GAPDH 30–300 000 3.31+0.01 0.9955+0.02
BORIS Prom A 30–300 000 3.51+0.12 0.9941+0.0078
BORIS Prom B 30–300 000 3.17+0.02 0.9945+0.004
BORIS Prom C 30–300 000 3.33+0.03 0.9943+0.0003
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Identification of transcription initiation sites using RNA
ligase-mediated rapid amplification of 5’ cDNA ends
(5’ RLM-RACE)
The GeneRacer system (Invitrogen, Carlsbad, CA, USA),
based on RNA ligase-mediated and oligo-capping rapid
ampliﬁcation of cDNA, was carried out based on the
manufacturer’s instructions. The kit ensures the ampliﬁca-
tion of only full-length transcripts by eliminating trun-
cated messages from the ampliﬁcation process. Total
RNA was dephosphorylated using calf intestinal
phosphatase and then decapped to target full-length
messenger RNAs. An RNA oligonucleotide was then
ligated to the full-length decapped mRNAs. Ligated
mRNA was reverse transcribed with a BORIS-speciﬁc
primer located in the ﬁrst exon (RACE-EX1
50-CAGAGGTACGCTCGGCCTCCAAC-30, +159 to
+138). Then the 50 cDNA end was ampliﬁed by nested
PCR using the GC-Rich PCR system (Roche) and with
BORIS-speciﬁc reversed primers (RACE-EX1N
50-GGCCTTTTTCCGGCATCAACT-30, +79 to +59;
RACE-N 50-TTGGGGTTGAAGTGGATGAGGAAG-30,
+1294 to +1271). Ampliﬁed products were separated by
electrophoresis on 1% agarose gels and puriﬁed on SNAP
columns (Invitrogen, Carlsbad, CA, USA). Puriﬁed PCR
fragments were cloned in a pCR2.1-TOPO vector
(Invitrogen), sequenced and analyzed.
Luciferase reporter vectors and p53 expression vectors
Fragments from the region 50 of BORIS were prepared by
PCR ampliﬁcation. The ampliﬁcation process introduced
Asp718I andHindIII sites in the 50 and 30 ends, respectively.
All fragments were inserted into the pGL3-basic vector
(Promega, Madison, WI, USA) cut with Asp718I and
HindIII.Wild type andmutant p53 expression vectors were
a generous gift from Dr Peter M. Chumakov.
Transient transfection and siRNA transfection assays
For luciferase assays, 293 cells were transiently transfected
using Fugene 6 (Roche, Germany) according to the manu-
facturer’s instructions. K562 cells were transfected with
a Nucleofector device (Amaxa, Inc., Cologne Germany)
according to the manufacturer’s recommendations with
Nucleofector Solution V and program T16 generating the
highest transfection eﬃciency with the lowest mortality.
HeLa, NCCIT and OVCAR-3 cells were seeded in 12-well
dishes at a concentration of 3 105 cells/well, one day
before transfection. The cells were transiently transfected
with the diﬀerent constructs (0.75 mg/well) with the
jetPEI Cationic Polymer Transfection reagent (4 ml/well)
(PolyPlus-transfection, Illkirch, France) according to
the manufacturer’s instructions. All experiments were
performed at least three times. The pRL-tk vector
(0.25 mg/well) (Promega, Madison, WI, USA) was
co-transfected as an internal control for transfection
eﬃciency. Luciferase assays were performed using the
Dual-Luciferase Reporter Assay System (Promega,
Madison, WI, USA). To compare results, the mean
values of relative luciferase activity were used. The
expression levels of the diﬀerent constructs were compared
to the level of the pGL3-control vector containing the
ﬁreﬂy luciferase gene under the control of the SV40 early
promoter and to the level of the pGL3-basic vector.
SiRNA assays were performed in 6-well plates using the
Interferin reagent (PolyPlus-transfection, Illkirch, France)
according to the manufacturer’s instructions. StealthTM
RNAi for CTCF 50-GCGCUCUAAGAAAGAAGAU
UCCUCU-30 was synthesized by Invitrogen (Invitrogen,
Carlsbad, CA, USA). StealthTM RNAi Negative Control
High GC siRNAs for silencing control was provided by
Invitrogen (Invitrogen, Carlsbad, CA, USA). Transfected
cells were harvested 48 h post-transfection.
DNAmethylation analysis of promoters B and C
DNA was extracted from frozen tissue or culture cells
using the DNeasy tissue kit (Qiagen, Hilden, Germany).
Two microgram of DNA were modiﬁed in 40 ml of water
with sodium bisulﬁte as previously described (31) or using
the EpiTect Bisulﬁte Kit (Qiagen, Hilden, Germany).
After bisulﬁte modiﬁcation, PCR on BORIS promoter B
was performed with the primers 50-CCTCCCCCAACCCT
ACCTAA-30 and 50-GTTTTTGGTTTGTGGGTTTT
GTT-30 using the master mix (Promega, Madison, WI,
USA) with a ﬁnal concentration of 5% DMSO, under the
following PCR conditions: 35 cycles of 948C for 30 s, 548C
for 45 s and 728C for 50 s. The ﬁrst PCR product diluted
1/50 was ampliﬁed by semi-nested-PCR with the primers
50-CACTACCACCCTCCACTCTC-30 (+931 to 1950)
and 0-GTTTTTGGTTTGTGGGTTTTGTT-30 (+964 to
+980). Each PCR product was analyzed by MS-SSCA
and MS-DBA (31,32), as previously described. In the MS-
DBA approach, two 30-end DIG-labeled probes,
50-AACCCGACGACGACCGAC-30 and 50-CCAACCC
AACAACAACCAAC-30, were used to recognize the
methylated and the unmethylated DNA, respectively.
PCR on BORIS promoter C were performed with primers
50-ACAAAACCCACAAACCAAAA-30 and 50-TTTTT
GGAGGAGAGTAGGTG-30 using the Platinum PCR
supermix (Invitrogen, Carlsbad, CA, USA) with a ﬁnal
concentration of 5% DMSO using the following PCR
conditions: 40 cycles at 948C for 30 s, 528C for 45 s and
728C for 50 s. PCR products ampliﬁed from NHDF,
NCCIT, OVCAR-3, K562 and OVCAR-8 cells were
cloned into pCR2.1-TOPO vector (Invitrogen,
Carlsbad, CA, USA). Ten clones for each cell lines were
sequenced (Genomics Research Facility, Rocky Mountain
Laboratories, NIAID/NIH, Montana, USA).
Electrophoretic mobility shift assay (EMSA)
Fragments containing BORIS promoters A, B and C were
synthesized by PCR. EMSA was performed as previously
described (33). Brieﬂy, PCR fragments were end labeled
using 32P-g-ATP and T4 polynucleotide kinase (New
England Biolabs). Protein–DNA complexes were allowed
to form by incubation for 30min at ambient temperature
in PBS with 5mM MgCl2, 0.1mM ZnSO4, 1mM
dithiothreitol, 0.1% Nonidet P-40, 10% glycerol and
poly(dI-dC). Full-length CTCF and the ZF DNA-binding
domain of CTCF were translated in vitro using the TnT kit
(Promega, WI, USA). Protein–DNA complexes were
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resolved from unbound DNA probe using a 5% native
polyacrylamide gel (PAAG) in 0.5 TBE.
Chromatin immunoprecipitation assay (ChIP)
Normal ﬁbroblast BJ cells and two cancer cell lines, Ovcar-
3 and Ovcar-8, were used in ChIP assays to examine the
in vivo binding of CTCF on BORIS promoters. We used a
ChIP Assay kit (Upstate, Charlotteville, VA, USA) and
followed the manufacturers’ recommendations. One ChIP
reaction used 10 ml of the anti-CTCF monoclonal anti-
bodies previously described (20). The human CTCF-
binding site N, a c-MYC insulator site (hMYC-N), was
used as positive control and CTCF non-binding site G of
c-MYC (hMYC-G) was used as negative control.
Immunopuriﬁed DNA was used in real-time PCR using
primers described in Table 2.
RESULTS
Identification ofBORIS transcription initiation sites
To identify transcription initiation sites, 50 RLM-RACE
was performed. The 50 RLM-RACE method has a major
advantage over other methods for mapping of transcrip-
tion start sites (e.g. primer extension, nuclease protection
assays or traditional 50 RACE) in that it only detects
authentic capped 50 ends of mRNAs. The technique is
based on RNA ligase-mediated (RLM-RACE) and oligo-
capping rapid ampliﬁcation of cDNA ends, and results in
the selective ligation of an RNA oligonucleotide to the
50 ends of decapped mRNA. This method allowed the
ampliﬁcation of only truly full-length transcripts via
elimination of truncated messages. The 50 RLM-RACE
assays were performed on total RNA extracted from
normal testis tissue, and from the NCCIT tumor cell line.
Two PCR products (700 bp and 1500 bp) were
obtained and, after cloning and sequencing, the ﬁrst
two start sites were identiﬁed at 658 and 899 bp from
the ATG translational start site (Figure 1A). Using
the GC-Rich PCR system and nested primers
upstream of the ﬁrst transcription start site, a 200 bp
PCR product was generated. This new site mapped to
1447 bp upstream of the ATG translation start
codon (Figure 1A).
Identification ofBORIS promoters and their
transcriptional activities
To functionally characterize the three putative promoters,
diﬀerent fragments of the regions upstream of all three
transcriptional start sites were cloned into a ﬁreﬂy
luciferase expressing vector (Figure 1B). Transfection
assays were carried out with the NCCIT, OVCAR-3
and HeLa cell lines. Two reporter constructs were used
to study transcriptional regulation by promoter A
(Figure 1B). The larger construct (2071 to 1276)
showed substantial transcriptional activity in all three
cell lines, whereas the 50 truncated construct (1413 to
1276) showed only low activity. The activity of promoter
A was signiﬁcantly higher in NCCIT than in OVCAR-3 or
HeLa cells. These results suggested that transcriptional
activity of promoter A could be cell type-speciﬁc. To study
transcriptional regulation by promoter B, three reporter
constructs were generated. The construct containing
nucleotides 1370 to 861 of the promoter B region
produced an activity that was 23–40% of that generated
by the SV40 promoter. A construct truncated to contain
nucleotides 1106 to 861 was more active, yielding
between 38% and 50% of SV40 levels, whereas the
transcriptional activity of the smallest construct (996 to
861) was very low. These results suggest that the
sequences located between 1106 and 996 to the ATG
translational start site deﬁned the minimal BORIS
promoter B. Promoter C is located very close to promoter
B and is quite small. To study promoter C, we generated
a construct containing nucleotides 821 to 622
upstream of the start site. This construct produced
relatively low activity in comparison with promoters A
and B. The transcriptional activity of promoter C was
observed to be higher in HeLa cells corresponding to 18%
of SV40 promoter activity, suggesting that promoter C
may also be tissue speciﬁc (Figure 1B).
Analyses of the BORIS promoter region sequences
using the MatInspector program (http://www.genomatix.
de/index.html) identiﬁed several consensus sequences for
transcription factor binding sites. In addition, promoters
B and C are situated in a CpG island. Promoter B
contained putative binding sites for Sp1, AP-2, NF-kB
and N-Myc and promoter C contained Sp1, two WT1,
AP-2 and EKLF putative binding sites (Figure 1A).
Promoter A contained Sp1, AP-2, CREB and a large
number of CAAT displacing protein (CDP) putative
binding sites.
Identification of five alternatively spliced 5’-UTRs for
BORIS and analyses of their stability
The fact that BORIS transcription initiated from three
diﬀerent promoters suggested that there would likely be a
series of 50 splice variants. Indeed, we identiﬁed ﬁve major
transcripts that diﬀered in their 50 noncoding regions but
encoded the same protein sequence (Figure 2). The BORIS
A1 and BORIS A3 isoforms are expressed from promoter
A and have ﬁrst 180 and 548 bp noncoding exons Ea
and Ea+Ea1+Eb, respectively that splice directly to the
ﬁrst 530 bp coding exon, E1. The BORIS A2 splice variant
also originates from promoter A, but has two more
noncoding exons, Ea1 and Eb, than the BORIS A1
isoform. The BORIS variant that comes from promoter B
contains a ﬁrst 80 bp noncoding exon, Eb, which splices to
ﬁrst 530 bp coding exon, E1. The BORIS C1 isoform is
expressed from promoter C and is transcribed as an
unspliced ﬁrst 1190 bp coding exon (Figure 2A). To
investigate whether the alternative 50 UTRs aﬀect
mRNA stability, we blocked RNA synthesis by treating
cells with ActD. Two cell lines were used in those
experiments: K562 cells that express all ﬁve alternative 50
UTRs and Ovcar-8 cells that express only two of ﬁve. As
shown in Figure 2 (panel B), the half-lives of BORIS,
BORIS A1, BORIS A2, BORIS A3 and BORIS C1
transcripts in K562 cells were 4.7, 7.4, 6.9, 7.9 and 6.4 h,
respectively, indicating that BORIS mRNAs in cultured
cells are relatively stable and long-lived. The alternative
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Figure 1. Identiﬁcation and activity of three BORIS promoters. (A) Nucleotide sequence of the 50-upstream region of the human BORIS gene is
shown together with a portion of the coding region. Potential binding sites of transcriptional regulatory proteins predicted by the MatInspector
program are shown in boxes. Yellow boxes highlight the Sp1 factor. The A in ATG translational start site is designated as nucleotide +1 and does
not appear in the ﬁgure. The main start sites for transcription, as determined by 50-RACE, are indicated by encircled blue arrows. The transcribed
sequences are underlined. Nucleotides of the CpG island are shaded in green. Red numbers (1–32) represent all CpGs within the CpG island.
(B) Determination of BORIS promoters A, B and C activities by transient expression of luciferase reporter constructs in HeLa, NCCIT and
OVCAR-3 cell lines. Left: schematic representation of BORIS promoter luciferase reporter constructs. Numbers indicate positions of nucleotides of
the 50-ﬂanking region of the BORIS gene, as shown in A. Right: relative luciferase activities compared with the pGL3 control vector activity, which
was considered to have 100% activity. The CpG island is shaded in green.
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transcript expressed from promoter B, BORIS, was
1.5-fold less stable than BORIS transcripts expressed
from promoters A and C. The relative turnover of
the three alternative 50 UTRs expressed from promoter
A—BORIS A1, BORIS A2 and BORIS A3—was compar-
able and the rates of degradation were approximately
1.2-fold slower than for the BORIS C1 transcript expressed
from promoter C. Similar half-lives of BORIS (4.7 h) and
BORIS C1 (6.6 h) were obtained in Ovcar-8 cell line
(Figure 2B). In both cell lines, GAPDH mRNA degrada-
tion was similar to published values for that gene (34).
Analysis of BORIS transcription from promoters A, B
and C in normal and cancer cells
To gain further insights into the characteristics of
promoters A, B and C, we studied their utilization by
qPCR in a panel of normal tissues, normal cell lines and
cancer cell lines. As expected from previous studies, testis
was the only normal tissue to express BORIS (data not
shown). The relative percent of expression from each
promoter was then calculated. Figure 3A shows that in
normal testis, expression comes from all three promoters.
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Figure 2. Detection of BORIS expression from diﬀerent alternative
promoters and stability of BORIS alternative transcripts. (A) Unique
BORIS cDNA sequences attached to promoters A, B and C. To detect
BORIS expression from diﬀerent promoters, forward primer was
designed on basis of unique cDNA sequence for every promoter.
Reverse primer was designed on the basis of BORIS coding exon 2
sequence. Expected RT-PCR fragment was 720 bp for BORIS promoter
A expression, 760 bp for BORIS promoter B expression and 810 bp for
BORIS promoter C expression. All RT-PCR fragments contain splice
site allowing distinguishing them from genomic DNA. (B) K562 and
Ovcar-8 cells were treated with Actinomycin D for various durations to
block transcription. Total RNA was extracted at the indicated time
points following the addition of actinomycin D. Quantitative real-time
PCR ampliﬁcation were performed as described in Materials and
Methods section to determine copy number of each BORIS alternative
transcript. Each data point represents the average of three ampliﬁcation
reactions. RNA degradation curves were obtained by setting at 100%
the maximum of mRNA expression at Time 0 before Act D treatment.
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Figure 3. BORIS expression from diﬀerent alternative promoters (A, B
and C) in normal testis and in multiple types of cancer cell lines by
real-time PCR. (A) Relative expression of BORIS from the three
diﬀerent promoters in normal testis. (B) Relative expression of BORIS
from the three diﬀerent promoters in 31 diﬀerent tumor cell lines.
Tumor cell lines are divided in four groups according to the main
promoter usage. Group B represents 16% of all cell lines tested and the
BORIS expression is mainly originated from promoter B. In the three
other groups the activity of BORIS comes from either promoter A,
either promoter C or from promoters A and C. These three groups
represent 84% of all cell lines tested.
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The distribution of activity is 47% from promoter A, 12%
from promoter B and 41% from promoter C.
The same analysis was performed on 31 cancer cell lines
(Table 1, Figure 3B). Only 5 cell lines showed transcrip-
tional activity promoter B and these were assigned to a
subset designated as group B. Activity in all the other cell
lines came only from promoters A or/and C. These 26 cell
lines were assigned to one of three groups, based on their
utilization of these two promoters. Group A is comprised
of cell lines that expressed BORIS primarily from
promoter A. Group C includes a series of cell lines that
expresses BORIS primarily from promoter C. Cell lines in
the group designated A/C use both promoters more or less
equally. The patterns of promoter utilization in the cancer
cell lines are distinct from that observed in normal testis.
However, it must be recognized that testis tissue contains
germ cells at various stages of spermatogenesis which
could utilize the diﬀerent promoters in a cell type-speciﬁc
manner or might use all three at each stage. Moreover,
based on known features of the 31 cell lines, preferential
promoter utilization could not be correlated with tissue
origin or with genomic characteristics that might be
thought to inﬂuence BORIS expression—loss of the
CTCF-containing chromosome 16; gain of chromosome
20 or ampliﬁcation of 20q13 that contains the BORIS
locus. In addition, there was no obvious relation between
promoter utilization and patterns of p53 expression
(Table 1) (35,36). These results showed that all three
promoters contribute to BORIS transcription, with cancer
cells preferentially using promoters A and C.
Regulation of BORIS promoters by CTCF
The fact that expression of CTCF and BORIS in normal
testis is almost mutually exclusive raised the possibility that
CTCF may negatively regulate BORIS transcription. To
examine this possibility, we used siRNA to suppress CTCF
expression in NHDF and then tested the cells for
expression of CTCF and BORIS by qPCR (Figure 4A).
We observed that the level ofCTCF transcript was reduced
more than 4-fold in cells expressing the siRNA while the
levels of BORIS transcripts in the same cells were increased
at least 8-fold (Figure 4A). To evaluate the contribution of
each promoter to expression of BORIS in the siRNA-
treated cells, we performed qPCR with primers and probes
speciﬁc for each of the spliced isoforms. The results showed
that in cells expressing the CTCF-speciﬁc siRNA, expres-
sion of BORIS from all three promoters was enhanced,
but to diﬀering extents—expression from promoter A
was increased 8–fold, expression from promoter B was
increased 2.5-fold, and expression from promoter C
was increased 4.5-fold (Figure 4A). These results indicated
that under normal circumstances, CTCF contributes to
suppression of BORIS expression by acting on all three
promoters.
To obtain additional evidence that CTCF binds directly
to the BORIS promoter region, we performed EMSA
using recombinant CTCF with overlapping probes
encompassing BORIS promoter sequences. We identiﬁed
3 binding sites in promoter A, 3 in promoter B and 2 in
promoter C (Figure 4B), supporting the suggestion that
CTCF is directly involved in suppressing BORIS expres-
sion. It is known that CTCF binding can be sensitive
(11–13,18,20) or insensitive to methylation of its target
sites (9,23,24). In order to see if CTCF binding within
BORIS promoters was sensitive to DNA methylation, all
fragments positive for CTCF binding were methylated
in vitro using SssI DNA methylase. EMSA analysis
showed that binding of the CTCF 11ZF DNA-binding
domain to fragments 2, 3, 4 (promoter A), 5 and 6
(promoter B) was similar whether the fragments were
methylated or not (Figure 4B). In contrast, no binding was
observed to methylated fragments 8, 9 and 10 that are
located in the CpG island shared by promoters B and C.
The degree of probe methylation, tested using the
methylation-sensitive restriction endonuclease AciI for
the BORIS promoter and BstUI for ICR4 as a positive
control, showed that the extent of methylation was nearly
100%. This experiment showed that some CTCF-binding
sites within BORIS promoters were methylation-sensitive
and others were methylation-insensitive.
To investigate CTCF binding to BORIS promoters
in vivo, we performed ChIP assays in normal BJ
ﬁbroblasts, in Ovcar-8, using mostly promoter B, and in
Ovcar-3, using mostly promoters A. We analyzed the
promoter regions of BORIS and site N from the c-MYC
locus, a well-characterized CTCF-binding site that func-
tions as a 50 chromatin insulator for the locus (3,20,37).
Figure 4C showed that site N was occupied by CTCF in
all three lines while the non-binding target used as
negative control was not. In the BJ cell line, occupancy
of all three promoters by CTCF correlated well with the
transcriptionally repressed state of all three in this cell line.
In Ovcar-8, CTCF occupancy was found only on
promoter A and C. No CTCF binding was found in
promoter B, which correlates with expression of BORIS
coming only from promoter B in this cell line (Table 1).
In contrast, CTCF binding in Ovcar-3 was identiﬁed in
promoter B but not in promoter C. CTCF binding in
promoter A was not signiﬁcant, showing only a 2.2-fold
enrichment. These results also correlate with BORIS
expression coming from promoters A and C, but not
from promoter B. Taken together, these results showed
that there was an inverse correlation between the extent to
which CTCF bound to the BORIS promoters and the
activity of those promoters.
Regulation of BORIS promoters by p53
In our analyses of BORIS expression in the 31 cancer cell
lines, we noted that the lines expressing BORIS at the
highest levels were known to have deletions or mutations
of TP53, the gene encoding the p53 tumor suppressor
(data not shown). This prompted us to ask if p53 might be
involved in regulating BORIS expression. To examine this
possibility, we transfected K562 cells that are p53 negative
with luciferase reporters for each of the three BORIS
promoters together with expression plasmids for wild-type
or mutant p53 (Figure 5A). The results of these studies
showed that the luciferase activity of all three BORIS
promoters was signiﬁcantly reduced in cells transfected
with wild-type p53 versus mutant p53. With wild-type p53,
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Figure 4. Regulation of BORIS expression by CTCF. (A) Real-time PCR analyses of RNA extracted from NHDF (Normal Human Dermal
Fibroblasts) treated with siRNA against CTCF show the decrease of CTCF expression and the increase of BORIS expression coming from the three
promoters at diﬀerent levels. Data were analyzed by comparative Ct method and normalized to the untreated control. Results are represented for
each set of primers used in real-time PCR. (B) Schematic map of the overlapping fragments used as EMSA probes for in vitro detection of CTCF-
binding sites and results of EMSA analyses showing binding of CTCF within promoters A, B and C in red (ﬁrst panel). Results of EMSA analyses of
SssI-methylated probes showing insensitivity of CTCF binding in promoter A and B, and methylation sensitive sites in promoter B and C within the
CpG island (second panel). The third panel showed the methylation-sensitive enzymatic restriction of probes used in methylation-sensitive EMSA.
(C) CTCF in vivo occupancy on BORIS promoters via ChIP in normal ﬁbroblasts BJ, Ovcar-8 and Ovcar-3 cell lines. Real-time PCR analysis of the
fold diﬀerence for the presence of DNA with the CTCF-binding site in the input chromatin versus in the CTCF chromatin fraction is obtained by
ChIP. The fold diﬀerence between immunoprecipitated DNA with speciﬁc CTCF antibody or rabbit serum (used as negative control) is represented
for each set of primers. hMYC-N primers are used as positive control for good enrichment after ChIP and c-MYC non-binding site G is used as
control for the speciﬁcity of the enrichment. Controls are represented in the right graph for each cell lines.
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the activity of promoters A and B was downregulated
about 3.3- and 4.6-fold, respectively, and the activity of
promoter C was repressed about 1.5-fold. We then per-
formed northern blot analysis of K562 cells transfected
with a vector encoding temperature-sensitive alleles
of wild-type and mutant p53. The results showed that
over-expression of the mutant p53 had no eﬀect on the
levels of either BORIS or CTCF transcripts. In contrast,
activation of wild-type p53 was associated with a great
reduction in expression of BORIS while expression of
CTCF was unaﬀected (Figure 5B). To further examine the
impact of p53 on BORIS expression in vivo, we compared
p53-negative H1299 parental cells with H1299 cells stably
infected with a virus expressing wild-type p53 (28). The
results (Figure 5C) showed that the level of p53 expression
was 12-fold higher in the virus-infected H1299 cells than
in the parental cells. Analyses of CTCF transcripts
showed that they were unchanged (data not shown).
In contrast, p53 had a profound eﬀect on each of the
three BORIS promoters. Expression from promoters
A and B was reduced 4.6- and 4.9-fold, respectively,
while that from promoter C was down 17-fold.
Regulation ofBORIS promoters by DNAmethylation
To further analyze the molecular mechanisms involved in
regulating the activity of the BORIS promoters, we
examined the eﬀect of CpG methylation. The fact that
promoters B and C co-localize within a CpG island raised
the possibility that their activities might be aﬀected by
methylation (Figure 1A). DNA samples from 2 cell lines,
24 human normal tissue samples and 26 tumor tissue
samples were extracted and analyzed by methylation-
sensitive single-strand conformation analysis (MS-SSCA)
and methylation-sensitive dot blot assay (MS-DBA) after
sodium bisulﬁte modiﬁcation (31,32). The CpG island was
found to be completely methylated in samples of all
normal tissues with the exception of testis, the tissue in
which BORIS is normally expressed. Studies of the CpG
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Figure 5. p53 eﬀect on BORIS promoters A, B and C activities. (A) Luciferase assays were performed by transient transfection of reporter constructs
and p53 wild-type (WT) or mutant (mut) expression vectors, in the p53/ K562 cell line. (B) Northern blot showing the expression of BORIS,
CTCF and p53 in the K562 p53 thermo-inducible cell line. (C) Real-time PCR on RNA extracted from p53/ H1299 parental cells or H1299 cells
expressing p53 wild type. Real-time PCR data were analyzed using the comparative Ct method and normalized to the non-induced cells.
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island in tumors revealed demethylation in testicular
tumors (6/6), ovarian tumors (1/3), breast cancers (1/6)
and endometrial tumors (1/3) (Table 4). Representative
examples of results from studies of the cell lines and tissues
are shown in Figure 6A. The partial methylation observed
in normal testis tissue is likely to be due to the presence of
both germ cells and non-germ cells in this tissue. As might
be expected, BORIS was expressed in almost all the
tumors and cell lines that contained a hypomethylated
CpG island. Moreover, it has been shown that
demethylation of BORIS promoter B in tumor tissues,
versus methylated BORIS promoter B in normal tissues, is
correlated with the expression of BORIS in tumors
(Table 4). However, among the 26 cell lines which
belong to group A/C, only 2 showed partial demethylation
of promoters B and C. Full methylation of these
promoters in all the other lines was correlated with
inhibition of BORIS transcription from promoter B
(Table 1). In the case of cell lines from group B, promoters
B and C were found to be unmethylated or partially
methylated in the case of COLO-205. Nine out of 32 CpGs
within promoters B and C were analyzed by genomic
bisulﬁte sequencing in NHDF, 2 cell lines from group A/C
(NCCIT and Ovcar-3) and 2 cell lines from group B
(Ovcar-8 and K562) (Figure 6B). In normal ﬁbroblasts,
98% of the CpGs analyzed were found to be methylated
and BORIS expression could not be detected. In NCCIT
and Ovcar-3, 98% and 96% of CpGs were methylated
(Figure 6B). In these cells, BORIS was expressed primarily
from promoter A, in association with minimal expression
from promoter C and no expression from promoter B
(Table 1). In Ovcar-8 and K562, sequencing showed that
0.9% and 0.45% of CpGs were methylated (Figure 6B). In
these two lines, expression of BORIS comes almost
exclusively from promoter B, 96% in Ovcar-8 and 80%
in K562 (Table 1).
To conﬁrm the regulation of promoter B by DNA
methylation, we treated two weakly BORIS-positive
cancer cell lines (HeLa and Co115) with 5-aza-dC.
Treatment resulted in demethylation of the CpG island
and strong activation of BORIS expression in both lines
(Figure 7A). Moreover, the real-time PCR analyses
showed that BORIS expression detected before 5-aza-dC
treatment was coming from promoters A and C, but
after 5-aza-dC treatment the BORIS expression switched
to promoter B in both cell lines (Figure 7B). The decrease
of expression from promoters A and C after 5-aza-dC
treatment might be explained by the eﬀect of 5-aza-dC
itself on other transcriptional factors that could also in
their turn downregulate BORIS expression through
promoters A and C. Expression of BORIS in normal
cells was also induced after treatment with 5-aza-dC
A
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Figure 6. Analyses of DNA methylation of BORIS promoter B.
(A) BORIS expression and methylation patterns of BORIS promoter B
in human tissues and cell lines. Lanes 1–2: MS-SSCA and MS-DBA
unmethylated and fully methylated controls respectively, obtained from
plasmids containing BORIS promoter B sequences; lanes 3–4: NCCIT
and OVCAR-3 cell lines; lanes 5–8: normal tissues, respectively colon,
skin, and two testis; lanes 9–13: tumor tissues, respectively bladder,
testis, ovary, breast, colon. BORIS mRNA was detected by RT-PCR,
with b-actine as internal control. (B) Genomic bisulﬁte sequencing of
16/32 CpGs within the CpG island covering promoters B in normal
ﬁbroblast NHDF, NCCIT (group A), Ovcar-3 (group A), Ovcar-8
(group B) and K562 (group B) cell lines.
Table 4. BORIS expression and BORIS promoter B methylation in
normal and tumor tissues
Normal
tissues
Tumor
tissues
BORIS expression Bladder  
Breast  + (1/6)
Colon  
Kidney  
Testis + +
Ovary  +
BORIS promoter B methylation Bladder + +
Breast +  (1/6)
Colon + +
Kidney + +
Testis  
Ovary +  (1/3)
Nucleic Acids Research, 2007, Vol. 35, No. 21 7383
 at Centro de Inform
ación y D
ocum
entación Científica on M
ay 28, 2012
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
(Figure 7C and D) with BORIS transcripts originating
from all three promoters. qPCR analyses showed that
BORIS transcripts from promoter B were readily detected
in cells treated for just 6 h and that transcripts from
all three promoters could be detected in cells treated for
24 h with promoter B being the strongest (Figure 7D).
Remarkably, we were not able to detect any demethyla-
tion of the CpG island at the 24 h time point, suggesting
that a mechanism other than demethylation was respon-
sible for the eﬀects of 5-aza-dC on the BORIS promoters.
DISCUSSION
In previous studies, it was shown that BORIS is normally
expressed only in male germ cells where it is involved
in epigenetic reprogramming (7,10). BORIS was also
shown to be a CTA and its transcription is abnormally
activated in varying proportions of a wide variety of
cancers (9,25,38–40). In some cancers, BORIS is the most
frequently activated CTA (40). Moreover, it has been
suggested that expression of BORIS may have diagnostic
implications (39), and recent work has identiﬁed BORIS
as an attractive candidate target for anti-cancer immu-
notherapy (41,42). The present study signiﬁcantly extends
these foundations by developing molecular understand-
ings of the mechanisms that tightly restrict BORIS
expression in normal tissues but are permissive for
expression in many malignancies.
Here, we ﬁrst identiﬁed three transcriptional start sites
at 1447, 899 and 658 bp upstream of the ﬁrst ATG of
the BORIS ORF. Regions upstream of those putative
transcriptional starts were tested in reporter assays and
were shown to exhibit promoter activities. These three
promoters designated A, B and C in association with the
start sites at 1447, 899 and 658, respectively induced
the synthesis of ﬁve transcripts that are diﬀerent from one
another in their 50-noncoding regions. Numerous studies
have documented the importance of 50-noncoding regions
for both mRNA stability (43–45) and translational
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Figure 7. Eﬀect of demethylating agent on BORIS expression in cancer cell lines and normal ﬁbroblasts. (A) BORIS expression and methylation
patterns of BORIS promoter B in two BORIS-negative cell lines treated with 5-aza-dC. Lanes 1–2: MS-SSCA unmethylated and fully methylated
controls respectively; lane 3: HeLa cells; lane 4: HeLa cells after 5-aza-dC treatment; lane 5: Co115 cells; lane 6: Co115 cells after 5-aza-dC treatment.
BORIS mRNA was detected by RT-PCR, with b-actine as internal control. (B) Real-time PCR on HeLa and Co115 before and after 5-aza-dC
treatment. Real-time PCR data were analyzed using the comparative Ct method between treated and untreated cells and for each set of primers. (C)
and (D) Determination of BORIS promoters A, B and C activities after treatment with 5-aza-dC of NHDFs by RT-PCR (C) and real-time PCR (D).
Real-time PCR data were analyzed using the comparative Ct method between treated and untreated cells and for each set of primers.
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eﬃciency (46), as well as for having an impact on the
speciﬁcity of tissue expression (47–49). Moreover, pro-
moter regions and 50-UTRs may determine alternative
splicing of downstream exons, thus inﬂuencing the
function of resulting products (50,51). We suggest that
similar regulatory mechanisms might well be involved in
the regulation of BORIS expression. In our study, we
estimated the half-life of BORIS transcripts with alter-
native 50 UTRs and found that the stability of the mRNAs
diﬀered signiﬁcantly. The variance ranged from 4.7 to
7.9 h, with the BORIS transcript having the shortest half-
life and the BORIS A3 transcript the longest. mRNA
stability plays a major role in gene expression in
mammalian cells, aﬀecting the rates at which mRNAs
disappear following transcriptional repression and accu-
mulate following transcription induction (29). Thus,
expression of BORIS alternative transcripts with diﬀerent
stabilities in testis and cancer cells suggests that these
isoforms may have unique physiological functions, possi-
bly related to diﬀerent stages of spermatogenesis or events
involved in cancer development and progression.
To understand these three promoters in greater depth,
we ﬁrst analyzed their utilization in a panel of normal
tissues and in 31 cancer cell lines representing diﬀerent
types of human tumors. We demonstrated that the extent
to which the promoters are employed is very diﬀerent for
normal testis and the cancer cell lines. In testis, all three
promoters are expressed but to diﬀering extents. Further
studies will be required to determine if this pattern is
common to all expressing germ cells or if promoter
utilization varies depending on the state of diﬀerentiation
with all being used at one point or another. In contrast,
the patterns of promoter utilization in BORIS-positive
cancer cell lines indicated that the lines fell into two
main subsets: group B, comprising 16% of the lines, in
which activity came primarily from promoter B; and
group A/C, with 84% of the cases, in which activities
come from promoters A and/or C. These results suggest
that the normally stringent restriction of BORIS expres-
sion to testis requires repression of all three promoters in
somatic cells. These data also demonstrate that release of
BORIS expression in cancers does not reﬂect relaxation
of promoter control to a state like that in testis but
occurs in a more selective mode of promoter deregulation.
Understanding if there are speciﬁc functional conse-
quences to selective regulation of each promoter and
variant transcript is a subject on ongoing studies.
As CTCF appears to be expressed in a complementary
fashion with BORIS during spermatogenesis, we evalu-
ated a potential inhibitory role for CTCF in BORIS
transcription. We demonstrated that downregulation of
CTCF by siRNA results in upregulation of BORIS in
NHDF. We also showed that all three BORIS promoters
contain CTCF-binding sites, suggesting that CTCF
acts directly to regulate the BORIS promoters. The
demonstration that CTCF is involved in the negative
regulation of BORIS expression is likely to be important
for understanding the uniform expression of BORIS
in normal rat cells transformed due to a retroviral
disruption of one CTCF allele (52) and in tumors
of mice heterozygous for a null allele of CTCF (unpub-
lished data).
Previous research convincingly demonstrated that
binding of CTCF to many of its targets is sensitive to
CpG methylation. This is exempliﬁed by studies of the
IGF2/H19 ICR, which showed that CTCF binds to the
unmethylated maternal allele but not the methylated
paternal allele (11–13). We thus hypothesized that
regulation of BORIS transcription would be dependent
on the methylation status of CTCF target sites in the
promoters. Consistent with this suggestion, BORIS
promoters B and C were found to be located in a shared
CpG island. We therefore proceeded to determine how
methylation status would aﬀect the activities of these
promoters. EMSAs performed using SssI methylated
probes showed that CTCF-binding sites in promoter A
were insensitive to methylation. In promoter B, however,
CTCF binding is insensitive to methylation outside of the
CpG island, but sensitive within the island. Likely, CTCF
binding in promoter C was sensitive to methylation. In
addition, ChIP studies showed a reverse correlation
between CTCF binding and expression of BORIS from
promoter B. Indeed, CTCF did not bind in promoter B in
Ovcar-8 cells that expressed BORIS from promoter B.
In contrast, CTCF bound strongly in promoter B in
Ovcar-3 cells that expressed BORIS from promoter A.
Analyses of methylation status of the CpG island in the
Ovcar-3 and BJ cell lines showed that promoters B and C
were fully methylated, although CTCF binding was found
in both promoters in vivo. It seems likely that these results
can be explained by the limitations of ChIP resolution as
promoter B also contains CTCF sites insensitive to
methylation and promoters B and C are only 250 bp
apart. However, the possibility of indirect CTCF recruit-
ment by another factor that can bind these methylated
sequences cannot be formally excluded. Analyses of
normal cells, tumor tissues and tumor cell lines showed
that the activity of promoter B is downregulated by
DNA methylation. Regulation of BORIS transcriptional
activity by methylation was suggested but not conclu-
sively demonstrated by other recent studies (9,53). As
shown here, treatment of cancer cell lines that express
BORIS at low levels with the demethylating agent,
5-aza-dC, resulted in demethylation of the promoter
CpG island and substantial increases in BORIS transcrip-
tion. However, treatment of BORIS-negative normal
ﬁbroblasts with 5-aza-dC also activated BORIS transcrip-
tion, this time from all three promoters. The rapidity
with which transcription was induced, and the lack of
demethylation of the CpG island that contains promoters
B and C, indicated that molecular mechanisms by which
5-aza-dC activated expression of BORIS in NHDF was
very diﬀerent from that governing activation in the tumor
cells. Based on this, we conclude that although the
methylation status of BORIS promoters is likely to be
the determining regulatory feature in many cellular
contexts, methylation-insensitive regulatory mechanisms
exist that may well be cell type-speciﬁc.
The tumor suppressor protein, p53, is well known as
a transcriptional activator of genes involved in cell cycle
arrest, apoptosis, DNA repair and senescence (54,55).
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Activation of transcription by p53 occurs mostly through
direct binding to DNA at a consensus target site. Never-
theless, in addition to gene activation through direct
binding to DNA, p53 has been shown to repress trans-
cription by indirect interactions with a target promoter
through a promoter-bound transcriptional activator as the
intermediary. For example, the interaction of p53 with
Sp1 inhibits hTERT (56), CCNB1 (57) and IGF1 (58)
promoters, while the interaction of p53 with NF-Y
inhibits CDC2 (59), FN1 (ﬁbronectin) (60) and COX2
(61) promoters. In this study, we showed that expression
of wild-type p53 protein resulted in repression of all three
BORIS promoters, but strongest forcefully for promoters
A and B. However, ChIP assays showed that p53 may not
bind directly to BORIS promoters (data not shown) or
that if bound, it may be masked by multiple p53-binding
co-factors from interactions with antibodies used in our
assay. It is also possible that the strong inhibitory eﬀects
of p53 on BORIS promoters could be explained by
interaction of p53 with the transcription factor Sp1 since
consensus-binding sites for Sp1 are present in several
copies in each BORIS promoter. Additionally, a recent
study showed that p53 is required for the maintenance of
DNA methylation patterns (62). Thus, it is possible that
the maintenance of DNA methylation by p53 (62) could
contribute to keeping BORIS silent.
In summary, we characterized three promoters for the
BORIS gene that lead to the transcription of ﬁve mRNA
diﬀering in their 50-UTRs. All three promoters were
involved in BORIS expression during normal spermato-
genesis; however, promoters A and C are preferentially
used upon activation of BORIS during tumorigenesis.
Interestingly, a few tumors that exhibited no activity from
any of these three promoters still expressed BORIS
transcripts (data not shown), suggesting the possible
existence of additional regulatory sequences that act
upstream of promoter A. Thus, DNA methylation, and
expression of CTCF and p53 represent three mechanisms
involved in the negative regulation of BORIS transcrip-
tion, although it seems likely that additional levels of
control also exist. These results showed that regulation of
BORIS activity is complex, being both promoter- and cell
type-dependent. Varying promoter usage driving multiple
BORIS transcripts could inﬂuence many aspects of
epigenetic reprogramming in normal development and in
tumorigenesis.
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